Cirrhosis

Cirrhosis

Summary

Intro:

The primary objective of this study is to assess the efficacy of rifaximin ssd-40ir versus placebo to delay the occurrence of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites. Participants who have cirrhosis determined by histopathological evidence, transient elastography or presence of esophageal varices, and who have not previously experienced OHE or spontaneous bacterial peritonitis (SBP) will be enrolled in the study.

Participant patient:

Male and non-pregnant, non-nursing females over 18 and under 85 years with liver cirrhosis and medically controlled ascites who have not previously experienced an episode of OHE or SBP. 

Full details:

For full details on this study, please contact us at (786) 432-3200. 

Delay of Hepatic Encephalopathy in Cirrhotic Patients

The delay of hepatic encephalopathy in cirrhotic patients refers to the use of medical interventions, lifestyle modifications, and therapies to prevent or prolong the onset of hepatic encephalopathy (he) in individuals who have liver cirrhosis. Hepatic encephalopathy is a neuropsychiatric complication that arises when the liver’s impaired function fails to remove toxins from the blood, leading to cognitive and neurological disturbances.

Description:

Hepatic encephalopathy is a significant complication of liver cirrhosis, a condition in which long-term damage to the liver causes scarring and impaired liver function. As the liver plays a central role in filtering toxins from the blood, its dysfunction can result in the accumulation of ammonia and other harmful substances, which can affect the brain.

Hepatic encephalopathy can range from mild cognitive impairment and subtle changes in behavior to severe confusion, disorientation, and even coma in advanced cases. It can significantly impact the quality of life for individuals with cirrhosis and may require hospitalization.

To delay or prevent the onset of hepatic encephalopathy in cirrhotic patients, various approaches can be taken:

  • Management of underlying liver disease: The primary goal is to manage and treat the underlying liver cirrhosis to slow down its progression and preserve liver function. This may involve lifestyle changes, medication, and, in some cases, interventions to address the causes of cirrhosis such as alcohol consumption or viral hepatitis.
  • Dietary modifications: Diet plays a crucial role in managing hepatic encephalopathy. A low-protein diet and restriction of dietary sources of ammonia are often recommended. Protein restriction helps minimize the production of ammonia in the gut.
  • Laxatives and enema: Laxatives and enemas can be used to promote regular bowel movements and prevent the accumulation of toxins in the intestines, which can contribute to hepatic encephalopathy.
  • Lactulose: Lactulose is a medication commonly prescribed to cirrhotic patients to lower ammonia levels by promoting the excretion of ammonia through the intestines.
  • Rifaximin: Rifaximin is an antibiotic that can reduce the growth of ammonia-producing bacteria in the gut, thus helping to lower ammonia levels in the blood.
  • Monitoring and early detection: Regular medical check-ups and monitoring of liver function are important for detecting any changes in liver health and addressing them before they lead to hepatic encephalopathy.

The effectiveness of these strategies can vary depending on the severity of liver cirrhosis and individual patient factors. Early diagnosis, regular medical care, and adherence to prescribed treatments are essential in managing cirrhosis and delaying the onset of hepatic encephalopathy. If you or someone you know has liver cirrhosis, it’s crucial to work closely with a healthcare provider to develop a personalized treatment plan.